Company Overview and News


Add TTNP
to your dashboard

Headline News

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Thank you for holding and welcome to the Titan Pharmaceuticals Third Quarter 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session following today’s remarks. Please be advised that this call is being taped at the Company’s request and will be archived on the Company’s website starting later today. (19-0)

Featured Company News - Titan Pharmaceuticals Announces First Patient Treatment for Parkinson's Disease in Phase-1/2 Trial with Ropinirole Implant

2017-10-13 accesswire
LONDON, UK / ACCESSWIRE / October 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=TTNP. The Company announced on October 11, 2017, the treatment of the first patient in Phase-1/2 trial, designed to evaluate the efficacy of the Ropinirole implant intended for the treatment of the signs and symptoms of idiopathic Parkinson's disease. (32-0)

First Patient Treated With Titan Pharmaceuticals' Subdermal Implant For Parkinson's Disease

2017-10-11 prnewswire
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that the first patient has been treated in a Phase 1/2 trial of the company's ropinirole implant intended for the treatment of the signs and symptoms of idiopathic Parkinson's disease. (16-1)

Corporate News Blog - Titan Pharma and Opiant Pharma Collaborate to Discover a New Approach for Treatment of Opioid Use Disorder

2017-10-04 accesswire
LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=TTNP. The Company announced on October 02, 2017, collaboration with Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) for exploring an innovative approach for the prevention of opioid relapse and overdose in individuals with opioid use disorder. (34-0)

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

2017-10-02 reuters
* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment (19-0)

Titan Pharmaceuticals To Present At Cantor Fitzgerald Global Healthcare Conference

2017-09-20 prnewswire
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that Titan President and CEO Sunil Bhonsle will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, Sept. (16-0)

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q2 2017 Results - Earnings Call Transcript

2017-08-10 seekingalpha
Thank you for holding and welcome to the Titan Pharmaceuticals Second Quarter 2017 Financial Results Conference Call. [Operator Instructions]. Please be advised that this call is being taped at the company's request and will be archived on the company's website starting later today.

Titan Pharma Schedules Conference Call To Review Second Quarter 2017 Financial Results

2017-08-03 devicespace
SOUTH SAN FRANCISCO, Calif., Aug. 2, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura long-term, continuous drug delivery technology, today announced that it will host a live conference call at 4:15 p.m. EDT / 1:15 p.m. PDT on Wednesday, Aug. 9, 2017 to discuss the company's financial results as of June 30, 2017.

Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q2 2017 Results - Earnings Call Transcript

2017-08-02 seekingalpha
Good afternoon, and welcome to Rigel Pharmaceutical's Financial Conference Call for the Second Quarter of 2017. All participants are in a listen-only mode. We will be facilitating a question-and-answer session at the end of today's conference. [Operator Instructions] I would like to remind you that this call is being recorded for replay purpose from Rigel's website. [Operator Instructions]

Titan Pharmaceuticals Secures $10 Million Debt Facility From Horizon Technology Finance

2017-07-27 prnewswire
SOUTH SAN FRANCISCO, Calif., July 27, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that it has entered into a venture loan and security agreement with Horizon Technology Finance Corporation (NASDAQ: HRZN), which provides Titan with up to $10 million of available borrowing capacity.

Titan Pharmaceuticals: Just Be Patient

2017-07-20 seekingalpha
On March 24, I wrote an article titled "Titan Pharmaceuticals: Bravery Will Be Rewarded (Just Maybe Not This Year". In it, I laid out three possible futures for Titan Pharmaceuticals (TTNP). Two estimates were of my own creation, and one was pulled from Zacks SCR. I had a conservative and an optimistic estimate that are detailed in the chart below. In my article I repeatedly explained why I thought Zacks' estimate was overly optimistic.

Titan Pharmaceuticals and Walter Reed Army Institute of Research Collaborate to Evaluate ProNeura Antimalarial Implants :: Titan Pharmaceuticals, Inc. (TTNP)

2017-07-06 titanpharm
SOUTH SAN FRANCISCO, Calif., July 6, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with Walter Reed Army Institute of Research (WRAIR) and Southwest Research Institute (SwRI) to evaluate the development of ProNeura-based implants for a long-term regimen in the prevention of malaria.

Big Pharma: Implants Could Replace Pills | Fortune.com

2017-07-03 fortune
Pills have been popped for aches, pains, and other medical problems for at least a few millennia. But are their days as the holy grail of drug delivery (and discovery) coming to an end?

CUSIP: 888314309